- Home
- BST vs PCRX Comparison
BST vs PCRX Comparison
Compare BST & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BST
- PCRX
- Stock Information
- Founded
- BST 2014
- PCRX 2006
- Country
- BST United States
- PCRX United States
- Employees
- BST N/A
- PCRX N/A
- Industry
- BST Finance Companies
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- BST Finance
- PCRX Health Care
- Exchange
- BST Nasdaq
- PCRX Nasdaq
- Market Cap
- BST 1.5B
- PCRX 1.2B
- IPO Year
- BST N/A
- PCRX 2011
- Fundamental
- Price
- BST $42.20
- PCRX $21.84
- Analyst Decision
- BST
- PCRX Buy
- Analyst Count
- BST 0
- PCRX 5
- Target Price
- BST N/A
- PCRX $32.40
- AVG Volume (30 Days)
- BST 92.9K
- PCRX 522.7K
- Earning Date
- BST 01-01-0001
- PCRX 10-31-2025
- Dividend Yield
- BST 7.21%
- PCRX N/A
- EPS Growth
- BST N/A
- PCRX N/A
- EPS
- BST N/A
- PCRX N/A
- Revenue
- BST N/A
- PCRX $705,848,000.00
- Revenue This Year
- BST N/A
- PCRX $7.27
- Revenue Next Year
- BST N/A
- PCRX $10.18
- P/E Ratio
- BST N/A
- PCRX N/A
- Revenue Growth
- BST N/A
- PCRX 2.25
- 52 Week Low
- BST $27.87
- PCRX $16.00
- 52 Week High
- BST $42.78
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- BST 62.99
- PCRX 32.78
- Support Level
- BST $41.00
- PCRX $21.24
- Resistance Level
- BST $41.80
- PCRX $23.23
- Average True Range (ATR)
- BST 0.65
- PCRX 0.82
- MACD
- BST -0.06
- PCRX -0.13
- Stochastic Oscillator
- BST 69.94
- PCRX 44.38
About BST BlackRock Science and Technology Trust of Beneficial Interest
BlackRock Science and Technology Trust is a closed-end management investment company. Its investment objective is to provide income and total return through a combination of current income, current gains, and long-term capital appreciation. It focuses on investing, under a normal market condition in equity securities of science and technology companies.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.